^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + SNK01 (NK cell stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Two-year efficacy of SNK01 plus pembrolizumab for non-small cell lung cancer: Expanded observations from a phase I/IIa randomized controlled trial
Published date:
06/06/2022
Excerpt:
This trial included 20 patients with advanced NSCLC with a PD-L1 tumor proportion score of 1% or greater....Among the 12 patients treated with pembrolizumab plus SNK01, five patients had a PD-L1 TPS of more than 50%, and seven patients had a PD-L1 TPS of less than 50%. The estimated 2 year PFS was 20.0% versus 28.6% in patients with PD-L1 < 50% and PD-L1 ≥ 50%, respectively....The 2 year OS was 42.9% versus 80.0% in patients with PD-L1 < 50% group and PD-L1 > 50%, respectively....Autologous NK cells can enhance the long-term OS and PFS for NSCLC.
DOI:
10.1111/1759-7714.14523
